首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Investigation into the promoter DNA methylation of three genes (CAMK1D CRY2 and CALM2) in the peripheral blood of patients with type 2 diabetes
【2h】

Investigation into the promoter DNA methylation of three genes (CAMK1D CRY2 and CALM2) in the peripheral blood of patients with type 2 diabetes

机译:2型糖尿病患者外周血三个基因(CAMK1DCRY2和CALM2)的启动子DNA甲基化研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Promoter DNA methylation may reflect the interaction between genetic backgrounds and environmental factors in the development of metabolic disorders, including type 2 diabetes (T2D). Calcium/calmodulin-dependent protein kinase 1D (CAMK1D), cryptochrome 2 (CRY2) and calmodulin 2 (CALM2) genes have been identified to be associated with a risk of T2D. Therefore, the aim of the present study was to investigate the contribution of promoter DNA methylation of these genes to the risk of T2D. Using bisulfite pyrosequencing technology, the DNA methylation levels of the CpG dinucleotides within the CAMK1D, CRY2 and CALM2 gene promoters were measured in 48 patients with T2D and 48 age- and gender-matched healthy controls. The results demonstrated that the promoters of these three genes were hypomethylated in the peripheral blood of all the subjects, and DNA methylation of these three genes did not contribute to the risk of T2D.
机译:启动子DNA甲基化可能反映了代谢性疾病(包括2型糖尿病(T2D))发展过程中遗传背景和环境因素之间的相互作用。钙/钙调蛋白依赖性蛋白激酶1D(CAMK1D),隐色染料2(CRY2)和钙调蛋白2(CALM2)基因已被确定与T2D风险相关。因此,本研究的目的是研究这些基因的启动子DNA甲基化对T2D风险的影响。使用亚硫酸氢盐焦磷酸测序技术,对48位T2D患者和48位年龄和性别相匹配的健康对照者的CAMK1D,CRY2和CALM2基因启动子内CpG二核苷酸的DNA甲基化水平进行了测量。结果表明,这三个基因的启动子在所有受试者的外周血中均被低甲基化,并且这三个基因的DNA甲基化对T2D的发生没有贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号